Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.
Abbreviated 12-week chemotherapy plus dual-targeted therapy achieved exceptional 5-year outcomes in HER2+ breast cancer, with blood tests potentially guiding safe treatment reduction.
Secondary analysis of the DAPHNe phase 2 trial demonstrates exceptional 5-year outcomes (EFS 99%, distant RFI 100%) for abbreviated 12-week neoadjuvant paclitaxel/trastuzumab/pertuzumab in stage II-III HER2+ breast cancer. Ultrasensitive ctDNA monitoring showed near-universal clearance (96.1%) after neoadjuvant therapy, providing strong rationale for ctDNA-guided treatment de-escalation.
What the study was
- Study design
- Prespecified secondary analysis of prospective single-arm phase 2 trial
- Population
- Stage II-III ERBB2-positive breast cancer patients (Dana-Farber + affiliates)
- Sample size
- 98
- Category
- Early Detection
- Maturity
- Potentially Practice-Changing
- Journal
- JAMA Oncology
Why it surfaced
First 5-year outcome data for abbreviated THP in HER2+ BC with real-world ctDNA monitoring; JAMA Oncology; supports major shift toward de-escalated neoadjuvant regimens with ctDNA-guided stratification.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.